Bokf Na lifted its position in West Pharmaceutical Services, Inc. (NYSE:WST – Get Rating) by 153.6% in the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 4,146 shares of the medical instruments supplier’s stock after acquiring an additional 2,511 shares during the period. Bokf Na’s holdings in West Pharmaceutical Services were worth $976,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Vestmark Advisory Solutions Inc. grew its stake in shares of West Pharmaceutical Services by 2.1% in the fourth quarter. Vestmark Advisory Solutions Inc. now owns 6,539 shares of the medical instruments supplier’s stock worth $1,539,000 after acquiring an additional 134 shares during the last quarter. CoreCap Advisors LLC bought a new stake in West Pharmaceutical Services during the 4th quarter valued at about $56,000. New York State Common Retirement Fund raised its holdings in West Pharmaceutical Services by 22.2% in the fourth quarter. New York State Common Retirement Fund now owns 141,997 shares of the medical instruments supplier’s stock worth $33,419,000 after buying an additional 25,775 shares during the last quarter. Korea Investment CORP grew its holdings in shares of West Pharmaceutical Services by 2.0% during the fourth quarter. Korea Investment CORP now owns 44,491 shares of the medical instruments supplier’s stock valued at $10,471,000 after buying an additional 881 shares during the last quarter. Finally, Geode Capital Management LLC increased its position in shares of West Pharmaceutical Services by 2.5% during the fourth quarter. Geode Capital Management LLC now owns 1,506,824 shares of the medical instruments supplier’s stock valued at $353,983,000 after acquiring an additional 36,935 shares in the last quarter. Hedge funds and other institutional investors own 91.51% of the company’s stock.
Insider Transactions at West Pharmaceutical Services
In other West Pharmaceutical Services news, VP Charles Witherspoon sold 1,000 shares of the firm’s stock in a transaction dated Tuesday, May 30th. The stock was sold at an average price of $343.05, for a total transaction of $343,050.00. Following the sale, the vice president now directly owns 1,829 shares of the company’s stock, valued at $627,438.45. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In related news, Director Thomas W. Hofmann sold 1,212 shares of the stock in a transaction that occurred on Monday, May 1st. The stock was sold at an average price of $365.57, for a total transaction of $443,070.84. Following the completion of the transaction, the director now directly owns 43,616 shares of the company’s stock, valued at $15,944,701.12. The sale was disclosed in a filing with the SEC, which is available through this link. Also, VP Charles Witherspoon sold 1,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 30th. The stock was sold at an average price of $343.05, for a total value of $343,050.00. Following the sale, the vice president now directly owns 1,829 shares in the company, valued at $627,438.45. The disclosure for this sale can be found here. Insiders sold a total of 67,244 shares of company stock valued at $24,454,553 over the last three months. Corporate insiders own 1.13% of the company’s stock.
West Pharmaceutical Services Stock Down 0.4 %
West Pharmaceutical Services (NYSE:WST – Get Rating) last released its earnings results on Thursday, April 27th. The medical instruments supplier reported $1.98 earnings per share for the quarter, beating the consensus estimate of $1.67 by $0.31. The company had revenue of $716.60 million for the quarter, compared to the consensus estimate of $697.28 million. West Pharmaceutical Services had a return on equity of 24.14% and a net margin of 19.15%. West Pharmaceutical Services’s quarterly revenue was down .5% compared to the same quarter last year. During the same period in the previous year, the business earned $2.30 earnings per share. On average, research analysts expect that West Pharmaceutical Services, Inc. will post 7.68 earnings per share for the current year.
West Pharmaceutical Services Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Wednesday, August 2nd. Shareholders of record on Wednesday, July 26th will be given a $0.19 dividend. The ex-dividend date is Tuesday, July 25th. This represents a $0.76 dividend on an annualized basis and a dividend yield of 0.22%. West Pharmaceutical Services’s payout ratio is currently 10.44%.
Wall Street Analysts Forecast Growth
Several equities analysts recently issued reports on the company. KeyCorp upped their price objective on West Pharmaceutical Services from $315.00 to $375.00 and gave the company an “overweight” rating in a research report on Friday, February 17th. Stephens raised West Pharmaceutical Services from an “equal weight” rating to an “overweight” rating and increased their price objective for the company from $330.00 to $400.00 in a research report on Tuesday, April 11th. StockNews.com raised shares of West Pharmaceutical Services from a “hold” rating to a “buy” rating in a report on Monday, June 5th. Finally, Deutsche Bank Aktiengesellschaft lifted their price target on shares of West Pharmaceutical Services from $250.00 to $290.00 in a research note on Wednesday, February 22nd. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $313.00.
About West Pharmaceutical Services
West Pharmaceutical Services, Inc manufactures and markets pharmaceuticals, biologics, vaccines and consumer healthcare products. It operates through the following business segments: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers proprietary packaging, containment and drug delivery products, along with analytical lab services, to biologic, generic and pharmaceutical drug customers.
Read More
- Get a free copy of the StockNews.com research report on West Pharmaceutical Services (WST)
- FuelCell Is Back To Realistic Valuation
- MarketBeat Week in Review – 6/4 – 6/9
- Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition
- Tax Software Specialist Vertex In Buy Zone After Base Breakout
- What is a Mutual Fund? How Does it Work?
Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.
